受体相互作用蛋白激酶2是胰腺癌的免疫治疗靶点
研究通过体内CRISPR筛选发现RIPK2是胰腺导管腺癌免疫逃逸的关键驱动因子,遗传或药物靶向RIPK2可使PDAC对anti-PD-1免疫治疗敏感,延长生存或实现完全消退。机制上肿瘤内在RIPK2缺失通过消除NBR1介导的自噬-溶酶体降解破坏促结缔组织增生性TME并恢复MHC-I表面水平。
要点
- RIPK2是PDAC免疫逃逸的关键驱动因子
- 靶向RIPK2使PDAC对anti-PD-1敏感,延长生存或完全消退
- RIPK2缺失破坏促结缔组织增生性TME并恢复MHC-I水平
核心结论
- 肿瘤内在RIPK2的遗传或药物靶向可改善PDAC对anti-PD-1免疫治疗的应答。
- 结果为RIPK2抑制联合anti-PD-1免疫治疗PDAC提供了新组合疗法的依据。
研究设计与样本
- 研究采用原位PDAC模型进行聚焦激酶组和膜蛋白组的CRISPR筛选。
- 开展机制研究探索肿瘤内在RIPK2缺失对TME和MHC-I的影响。
主要发现
- RIPK2是细胞毒性T细胞杀伤免疫逃逸的关键驱动因子。
- 遗传或药物靶向RIPK2使PDAC对anti-PD-1免疫治疗敏感,导致生存延长或完全消退。
- 肿瘤内在RIPK2缺失通过消除NBR1介导的自噬-溶酶体降解破坏促结缔组织增生性TME并恢复MHC-I表面水平。
临床怎么用
- 作者认为RIPK2抑制联合anti-PD-1免疫治疗是PDAC的新型组合治疗策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy because of its aggressive nature and the paucity of effective treatment options. Almost all registered drugs have proven ineffective in addressing the needs of patients with PDAC. This is the result of a poor understanding of the unique tumor-immune microenvironment (TME) in PDAC. To identify druggable regulators of immunosuppressive TME, we performed a kinome- and membranome-focused CRISPR screening using orthotopic PDAC models. Our data showed that receptor-interacting protein kinase 2 (RIPK2) is a crucial driver of immune evasion of cytotoxic T-cell killing and that genetic or pharmacologic targeting of RIPK2 sensitizes PDAC to anti-programmed cell death protein 1 (anti-PD-1) immunotherapy, leading to prolonged survival or complete regression. Mechanistic studies revealed that tumor-intrinsic RIPK2 ablation disrupts desmoplastic TME and restores MHC class I (MHC-I) surface levels through eliminating NBR1-mediated autophagy-lysosomal degradation. Our results provide a rationale for a novel combination therapy consisting of RIPK2 inhibition and anti-PD-1 immunotherapy for PDAC. SIGNIFICANCE: PDAC is resistant to almost all available therapies, including immune checkpoint blockade. Through in vivo CRISPR screen, we identified that RIPK2 plays a crucial role in facilitating immune evasion by impeding antigen presentation and cytotoxic T-cell killing. Targeting tumor-intrinsic RIPK2 either genetically or pharmacologically improves PDAC to anti-PD-1 immunotherapy. See related commentary by Liu et al., p. 208 . This article is featured in Selected Articles from This Issue, p. 201.
引用
- Sang W, Zhou Y, Chen H, et al. Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer. Cancer Discov. 2024. PMID: 37824278. doi:10.1158/2159-8290.CD-23-0584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。